论文部分内容阅读
探讨Fas、FasL系统表达、突变与大肠癌转移的关系。方法 :采用RT -PCR和PCR -SSCP方法检测大肠癌原发灶、肝转移灶、癌旁肠粘膜、门静脉血淋巴细胞中Fas、FasL表达、突变。结果 :在 86例大肠癌原发灶、肝转移灶、癌旁肠粘膜、门静脉血淋巴细胞中Fas表达阳性率分别为 67.4 % ,63 .2 % ,4 1.9% ,87.2 %。Fas突变率分别为 50 .0 % ,70 .8% ,2 5.% ,8.0 %。在大肠癌原发灶、肝转移灶中Fas突变率较高 (P <0 .0 1)。3 8例肝转移灶中全部有FasL表达 ,而在原发灶、癌旁肠粘膜、门静脉血淋巴细胞中FasL表达阳性率分别为2 5.6% ,14 .0 % ,50 .0 %。肝转移灶中FasL表达高于其它组织 (P <0 .0 1)。结论 :Fas突变和FasL增强表达是大肠癌细胞逃避免疫监视和杀伤并发生肝转移的机制之一。
To investigate the relationship between the expression of Fas and FasL and the metastasis of colorectal cancer. Methods: RT-PCR and PCR-SSCP were used to detect the expression of Fas and FasL in primary colorectal cancer, hepatic metastases, para-cancerous intestinal mucosa and portal vein lymphocytes. Results: The positive rate of Fas in 86 cases of primary colorectal cancer, liver metastasis, adjacent colorectal mucosa and portal vein lymphocytes were 67.4%, 63.2%, 41.9% and 87.2% respectively. Fas mutation rates were 50.0%, 70.8%, 25.5% and 8.0% respectively. In primary colorectal cancer, the frequency of Fas mutation in liver metastases was higher (P <0.01). FasL expression was found in all 38 liver metastases, while the positive rates of FasL expression in the primary tumor, paracancer intestinal mucosa and portal vein lymphocytes were 25.6%, 14.0% and 50.0%, respectively. The expression of FasL in liver metastasis was higher than that in other tissues (P <0.01). CONCLUSION: Fas mutation and FasL expression are one of the mechanisms of colorectal cancer cells in avoiding immune surveillance and killing and liver metastasis.